Any reported side effects with cosentyx and breastfeeding?

Can Cosentyx pass into breast milk?

Limited clinical data exists on secukinumab excretion into breast milk. Animal studies show low transfer, but human trials remain sparse.

What side effects have been reported in breastfeeding mothers taking Cosentyx?

No specific maternal side effects tied to breastfeeding have been reported. Mothers taking secukinumab during lactation report the usual range of Cosentyx adverse events, mainly upper respiratory infections and diarrhea.

Are infants exposed through breast milk at risk?

Infants exposed to secukinumab through breast milk may face theoretical risk of immune suppression. No cases of infant infections or developmental issues have been documented in available data.

How long does Cosentyx stay in the body during lactation?

Secukinumab has a half-life of 25–28 days. This extends exposure windows beyond termination of therapy, so mothers should discuss timing with their provider.

What do guidelines say about Cosentyx use during breastfeeding?

Current guidelines recommend weighing risks versus benefits rather than absolute contraindication. Providers often advise pumping and discarding milk for a set period after injection or switching to alternative therapies.

What alternatives exist if Cosentyx is discontinued during lactation?

Topical treatments or older biologic agents with more lactation data, such as etanercept or infliximab, may provide options for mothers who stop secukinumab.

When does Cosentyx lose exclusivity?

Cosentyx exclusivity expired in 2023. Biosimilar versions are now entering the market, affecting availability and pricing.

Who manufactures Cosentyx?

Novartis manufactures und develops Cosentyx.